Characteristics of the patients who should in theory have been treated according to the 2012 PMOP guidelines and comparison of the patients who were actually treated against those who were not.
| Characteristics | Total, n = 212 | No Treatment, n = 162 | Treatment, n = 50 | p |
|---|---|---|---|---|
| Age, yrs | 66.0 ± 7.9 | 65.4 ± 7.5 | 68.2 ± 8.7 | 0.03 |
| Higher education | 63 (29.7) | 50 (30.9) | 13 (26.0) | 0.64 |
| Weight, kg | 62.1 ± 11.4 | 63.4 ± 11.9 | 58.1 ± 8.6 | 0.004 |
| BMI, kg/m2 | 24.5 ± 4.4 | 24.9 ± 4.5 | 23.2 ± 3.9 | 0.02 |
| BMI < 19 kg/m2 | 14 (6.6) | 9 (5.6) | 5 (10.0) | 0.20 |
| RA duration, yrs | 20.8 ± 10.3 | 19.8 ± 9.4 | 24.2 ± 12.4 | 0.008 |
| DAS28-ESR score | 2.9 ± 1.3 | 2.9 ± 1.3 | 2.8 ± 1.3 | 0.84 |
| DAS28-CRP score | 2.8 ± 1.1 | 2.7 ± 1.1 | 2.8 ± 1.1 | 0.80 |
| SDAI score | 7.5 (4.1–14.1) | 7.2 (4.1–14.1) | 9.0 (3.1–14.1) | 0.87 |
| CDAI score | 7.0 (4.0–13.0) | 7.0 (4.0–13.0) | 9.0 (2.5–13.5) | 0.72 |
| HAQ score | 0.25 (0.00–0.75) | 0.25 (0.00–0.62) | 0.37 (0.00–0.75) | 0.17 |
| Physical activity ≥ 30 min/day | 130 (61.3) | 104 (64.2) | 26 (52.0) | 0.17 |
| Renal failure | 21/209 (10.0) | 20/160 (12.5) | 1/49 (2.0) | 0.07 |
| No. comorbidities | 0 (0–1) | 0 (0–1) | 0 (0–1) | 0.46 |
| ≥ 1 comorbidity | 102 (48.1) | 79 (48.8) | 23 (46.0) | 0.99 |
| Current prednisone, mg/day | 0 (0–4) | 0 (0–4) | 0 (0–4) | 0.64 |
| Prednisone equivalent since M6, mg | 240 (0–3625) | 210 (0–3430) | 940 (0–4080) | 0.60 |
| NSAID | 51 (24.1) | 43 (26.5) | 8 (16.0) | 0.16 |
| Biologic agents* | 168 (79.2) | 130 (80.2) | 38 (76.0) | 0.23 |
| Prior fracture | 99 (46.7) | 69 (42.6) | 30 (60.0) | 0.06 |
| Lumbar spine T score | −1.4 (−2.3 to −0.6) | −1.3 (−2.2 to −0.5) | −2.2 (−3.0 to −1.1) | 0.003 |
| Femoral neck T score | −1.9 (−2.4 to −1.5) | −1.8 (−2.3 to −1.3) | −2.2 (−2.9 to −1.9) | 0.001 |
| Femoral T score | −1.6 (−2.1 to −0.9) | −1.5 (−2.0 to −0.8) | −1.7 (−2.7 to −1.6) | 0.07 |
| At least 1 T score ≤ −1.5 | 158/197 (80.2) | 118/153 (77.1) | 40/44 (90.9) | 0.06 |
| At least 1 T score ≤ −2.5 | 73/197 (37.1) | 47/153 (30.7) | 26/44 (59.1) | 0.001 |
| At least 1 T score ≤ −3 | 45/181 (24.9) | 30/147 (20.4) | 15/34 (44.1) | 0.006 |
| FRAX, unadjusted | 17.9 ± 12.1 | 16.3 ± 10.8 | 23.2 ± 14.7 | 0.002 |
| FRAX, adjusted | 15.6 ± 11.2 | 14.2 ± 9.8 | 20.4 ± 4.2 | 0.002 |
Values are frequencies (%), mean ± SD, or median (interquartile range).
↵* Biologic agents: TNF inhibitor, abatacept, rituximab, or tocilizumab. PMOP: postmenopausal osteoporosis; BMI: body mass index; RA: rheumatoid arthritis; CDAI: clinical disease activity index; DAS28-CRP: 28-joint count Disease Activity Score using C-reactive protein; DAS28-ESR: DAS28 using erythrocyte sedimentation rate; HAQ: Health Assessment Questionnaire; M6: Month 6; NSAID: nonsteroidal antiinflammatory drugs; SDAI: Simple Disease Activity Index; FRAX: World Health Organization fracture risk assessment tool; TNF: tumor necrosis factor.